Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment.
Thi-Van-Trinh TranCarole RubinoRodrigue Setcheou AllodjiMilena AndruccioliStéphane BardetIbrahima DialloMassimo DottoriniJérome GarsiPer HallMichel Henry-AmarStephanie LamartFrançoise Le ThaiStefan LönnMarcel RicardClaire SchvartzMartin SchlumbergerNeige JournyFlorent de VathairePublished in: British journal of cancer (2022)
An elevated risk was observed for the highest cumulative administered activity (>=400 mCi), and a significant dose-dependent association was observed among thyroid cancer survivors who were treated with I-131. However, overall, I-131 treatment might only explain partly the increase in breast cancer risk among female thyroid cancer survivors.